PURPOSE: To evaluate the impact of tumor location, clinical parameters, and therapy on neurocognitive, neuroendocrine, and functional outcomes in children < or = 3 years old with intracranial CNS malignancies who survived at least 2 years after diagnosis. PATIENTS AND METHODS: Records were retrospectively reviewed for 194 children diagnosed from 1985 to 1999 at St Jude Children's Research Hospital (Memphis, TN). RESULTS: The median age at diagnosis was 1.8 years (range, 0.1 to 3.5 years). Median follow-up was 7.64 years (2.0 to 19.4 years). Tumors were infratentorial (102), diencephalic (53), and hemispheric (39); 47% required ventriculoperitoneal shunts, 36% developed seizure disorders, and 20% developed severe ototoxicity. Therapy included no radiation therapy (RT) in 57 (30%), local RT in 87 (45%), and craniospinal irradiation (CSI) in 49 (25%). Overall survival at 10 years was 78 +/- 4%. In a longitudinal analysis of 126 patients with at least one neurocognitive evaluation (NE), the mean rate of intelligence quotient (IQ) change for patients who received CSI (-1.34 points per year) and local RT (-0.51 points per year) was significantly different from the no RT group (0.91 points per year; P = .005 and P = .036, respectively). Patients with hemispheric tumors had a significantly greater IQ decline (-1.52 points per year) than those with midline tumors (0.59 points per year; P = .038). Among those with NE > or = 5 years after diagnosis, 71.4% of CSI recipients compared with 23% of local RT recipients had IQ less than 70 (P = .021). Patients undergoing CSI were more likely to develop endocrinopathies (P < .0001) and to require special education (P = .0007). CONCLUSION: In young children with CNS tumors, CSI and hemispheric location are associated with significant declines in IQ scores.
PURPOSE: To evaluate the impact of tumor location, clinical parameters, and therapy on neurocognitive, neuroendocrine, and functional outcomes in children < or = 3 years old with intracranial CNS malignancies who survived at least 2 years after diagnosis. PATIENTS AND METHODS: Records were retrospectively reviewed for 194 children diagnosed from 1985 to 1999 at St Jude Children's Research Hospital (Memphis, TN). RESULTS: The median age at diagnosis was 1.8 years (range, 0.1 to 3.5 years). Median follow-up was 7.64 years (2.0 to 19.4 years). Tumors were infratentorial (102), diencephalic (53), and hemispheric (39); 47% required ventriculoperitoneal shunts, 36% developed seizure disorders, and 20% developed severe ototoxicity. Therapy included no radiation therapy (RT) in 57 (30%), local RT in 87 (45%), and craniospinal irradiation (CSI) in 49 (25%). Overall survival at 10 years was 78 +/- 4%. In a longitudinal analysis of 126 patients with at least one neurocognitive evaluation (NE), the mean rate of intelligence quotient (IQ) change for patients who received CSI (-1.34 points per year) and local RT (-0.51 points per year) was significantly different from the no RT group (0.91 points per year; P = .005 and P = .036, respectively). Patients with hemispheric tumors had a significantly greater IQ decline (-1.52 points per year) than those with midline tumors (0.59 points per year; P = .038). Among those with NE > or = 5 years after diagnosis, 71.4% of CSI recipients compared with 23% of local RT recipients had IQ less than 70 (P = .021). Patients undergoing CSI were more likely to develop endocrinopathies (P < .0001) and to require special education (P = .0007). CONCLUSION: In young children with CNS tumors, CSI and hemispheric location are associated with significant declines in IQ scores.
Authors: T de Rojas; M Puertas; F Bautista; I de Prada; M Á López-Pino; B Rivero; C Gonzalez-San Segundo; M Gonzalez-Vicent; A Lassaletta; L Madero; L Moreno Journal: Clin Transl Oncol Date: 2019-04-01 Impact factor: 3.405
Authors: M Douglas Ris; Wendy M Leisenring; Pamela Goodman; Chongzhi Di; Jennie Noll; Wendy Levy; Leslie L Robison; Gregory T Armstrong Journal: Cancer Date: 2019-06-24 Impact factor: 6.860
Authors: Matija Snuderl; Ana Batista; Nathaniel D Kirkpatrick; Carmen Ruiz de Almodovar; Lars Riedemann; Elisa C Walsh; Rachel Anolik; Yuhui Huang; John D Martin; Walid Kamoun; Ellen Knevels; Thomas Schmidt; Christian T Farrar; Benjamin J Vakoc; Nishant Mohan; Euiheon Chung; Sylvie Roberge; Teresa Peterson; Carlos Bais; Boryana H Zhelyazkova; Stephen Yip; Martin Hasselblatt; Claudia Rossig; Elisabeth Niemeyer; Napoleone Ferrara; Michael Klagsbrun; Dan G Duda; Dai Fukumura; Lei Xu; Peter Carmeliet; Rakesh K Jain Journal: Cell Date: 2013-02-28 Impact factor: 41.582
Authors: Jean M Mulcahy Levy; Tiffany Tello; Roger Giller; Greta Wilkening; Ralph Quinones; Amy K Keating; Arthur K Liu Journal: Pediatr Blood Cancer Date: 2012-07-27 Impact factor: 3.167
Authors: Sun Young Kim; Ki Woong Sung; Jeong Ok Hah; Keon Hee Yoo; Hong Hoe Koo; Hyoung Jin Kang; Kyung Duk Park; Hee Young Shin; Hyo Seop Ahn; Ho Joon Im; Jong Jin Seo; Yeon Jung Lim; Young Ho Lee; Hyung Jin Shin; Do Hoon Lim; Byung Kyu Cho; Young Shin Ra; Joong Uhn Choi Journal: Korean J Hematol Date: 2010-06-30